Elanco Animal Health (NYSE:ELAN) Announces Earnings Results, Beats Expectations By $0.07 EPS

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Friday. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.07, FiscalAI reports. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period in the prior year, the company earned $0.19 EPS. Elanco Animal Health’s revenue for the quarter was up 11.3% on a year-over-year basis. Elanco Animal Health updated its Q4 2026 guidance to 0.160-0.190 EPS and its FY 2026 guidance to 1.170-1.200 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 11% revenue growth in Q3, or 9% organic constant currency, and exceeded its guidance for revenue, adjusted EBITDA and adjusted EPS. The company raised full-year 2026 guidance, including adjusted EPS to $1.17–$1.20.
• Innovation products powered growth: Q3 innovation revenue rose 40% to $328 million, led by Zenrelia and Credelio Quattro, with both reaching record U.S. market share in September. Elanco raised its 2026 innovation revenue target to $1.275 billion and expects Befrena to be a significant U.S. Pet Health growth driver in 2027.
• Adjusted gross margin expanded 300 basis points to 56.1%, while the company generated $362 million in year-to-date free cash flow and reduced net leverage to 2.9 times. Management said productivity initiatives and growing innovation sales support further margin improvement.
• Management expects Q4 organic growth to moderate to 4%–6%, and flagged 2027 offsets including Costco’s non-renewal, regional farm-animal cycles, persistent inflation and initially dilutive Befrena growth. Elanco nevertheless reiterated its 2027 growth algorithm and expects pet health to outperform farm animal.
• Executives described competition as generally responsible but noted targeted promotions and corporate-account offers in parts of the market. They said these tactics may shift sales timing, but maintained that they do not expect a material change to the trajectory of share gains.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $25.65 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. Elanco Animal Health has a 1-year low of $19.40 and a 1-year high of $27.98. The stock has a market capitalization of $12.81 billion, a P/E ratio of -85.48, a P/E/G ratio of 2.28 and a beta of 1.73. The business has a 50-day moving average price of $23.13 and a two-hundred day moving average price of $23.82.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O’Neill purchased 3,998 shares of the stock in a transaction dated Tuesday, August 18th. The stock was bought at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the transaction, the insider directly owned 87,832 shares in the company, valued at $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael Harrington purchased 5,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director owned 131,451 shares in the company, valued at $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 48,998 shares of company stock worth $1,139,373 over the last quarter. Company insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of several research reports. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. UBS Group raised their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their target price for the stock from $31.00 to $24.00 in a research note on Tuesday, October 20th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. Finally, Morgan Stanley decreased their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

About Elanco Animal Health

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.